Cognition Therapeutics (CGTX)
Cognition Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
7.0M
Short interest
settlement 2026-10-15
9.9
Days to cover
-6.7 days vs prior
56.0%
Short share of volume
2026-11-02
13,905
Fails to deliver
settlement 2026-10-13
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CGTX is 7,037,336 shares, down 703,661 shares over the last month. Over the last 48 readings it ranged from 222,751 shares (14 February 2025) to 9,676,308 shares (15 July 2026). At the reported average volume of 708K shares a day that is 9.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cgtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,037,336 | -7.2% | 707,897 | 9.94 |
| 2026-09-30 | 7,579,141 | -2.1% | 455,659 | 16.63 |
| 2026-09-15 | 7,740,997 | -1.5% | 342,552 | 22.60 |
| 2026-08-31 | 7,861,016 | +10.3% | 386,413 | 20.34 |
| 2026-08-14 | 7,125,319 | -20.2% | 708,921 | 10.05 |
| 2026-07-31 | 8,927,120 | -7.7% | 422,793 | 21.11 |
| 2026-07-15 | 9,676,308 | +36.9% | 2,012,207 | 4.81 |
| 2026-06-30 | 7,067,665 | -5.9% | 3,174,670 | 2.23 |
| 2026-06-15 | 7,511,832 | +16.9% | 1,304,537 | 5.76 |
| 2026-05-29 | 6,423,338 | -17.2% | 832,444 | 7.72 |
| 2026-05-15 | 7,758,314 | -2.8% | 804,072 | 9.65 |
| 2026-04-30 | 7,981,358 | +9.1% | 1,250,533 | 6.38 |
| 2026-04-15 | 7,317,585 | +6.8% | 1,108,850 | 6.60 |
| 2026-03-31 | 6,854,945 | -2.1% | 1,834,333 | 3.74 |
| 2026-03-13 | 7,004,362 | -1.9% | 654,207 | 10.71 |
| 2026-02-27 | 7,139,534 | -3.2% | 615,881 | 11.59 |
| 2026-02-13 | 7,378,713 | +1.9% | 797,055 | 9.26 |
| 2026-01-30 | 7,242,065 | +5.0% | 1,102,011 | 6.57 |
| 2026-01-15 | 6,896,939 | +19.1% | 893,786 | 7.72 |
| 2025-12-31 | 5,791,349 | -10.0% | 951,215 | 6.09 |
| 2025-12-15 | 6,436,771 | +0.6% | 942,710 | 6.83 |
| 2025-11-28 | 6,396,928 | -12.8% | 927,162 | 6.90 |
| 2025-11-14 | 7,336,255 | -1.0% | 1,066,988 | 6.88 |
| 2025-10-31 | 7,408,085 | -12.2% | 1,299,164 | 5.70 |
| 2025-10-15 | 8,436,248 | +18.2% | 2,263,905 | 3.73 |
| 2025-09-30 | 7,136,374 | -20.7% | 2,526,324 | 2.82 |
| 2025-09-15 | 9,001,537 | -2.2% | 4,784,035 | 1.88 |
| 2025-08-29 | 9,205,855 | +47.8% | 11,217,028 | 1.00 |
| 2025-08-15 | 6,226,969 | +17.1% | 11,713,979 | 1.00 |
| 2025-07-31 | 5,319,846 | -28.3% | 5,648,247 | 1.00 |
| 2025-07-15 | 7,414,526 | +281.3% | 33,511,274 | 1.00 |
| 2025-06-30 | 1,944,322 | +26.4% | 1,139,240 | 1.71 |
| 2025-06-13 | 1,538,143 | +103.0% | 2,661,896 | 1.00 |
| 2025-05-30 | 757,886 | -43.6% | 718,726 | 1.05 |
| 2025-05-15 | 1,344,288 | +47.3% | 1,430,540 | 1.00 |
| 2025-04-30 | 912,904 | +0.1% | 377,083 | 2.42 |
| 2025-04-15 | 911,872 | -40.8% | 682,349 | 1.34 |
| 2025-03-31 | 1,540,416 | +8.7% | 534,708 | 2.88 |
| 2025-03-14 | 1,416,555 | -32.8% | 782,246 | 1.81 |
| 2025-02-28 | 2,109,248 | +846.9% | 5,437,015 | 1.00 |
| 2025-02-14 | 222,751 | -57.5% | 673,572 | 1.00 |
| 2025-01-31 | 523,875 | -16.2% | 919,120 | 1.00 |
| 2025-01-15 | 624,874 | -65.4% | 1,791,087 | 1.00 |
| 2024-12-31 | 1,807,426 | +23.3% | 32,538,001 | 1.00 |
| 2024-12-13 | 1,466,065 | -45.4% | 1,262,744 | 1.16 |
| 2024-11-29 | 2,683,805 | +271.2% | 6,476,934 | 1.00 |
| 2024-11-15 | 722,954 | -11.4% | 358,567 | 2.02 |
| 2024-10-31 | 815,696 | +66.2% | 812,196 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of CGTX volume is 56.0%, up 18.5 points over the last five sessions. Over the last 30 readings it ranged from 16.7% (12 October 2026) to 79.1% (23 September 2026). The latest reading is 6.4 points above the 30-session average of 49.6%, on 210K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 118K | 210K | 56.0% | 2,000 |
| 2026-10-30 | 136K | 298K | 45.8% | 3,092 |
| 2026-10-29 | 53K | 108K | 48.7% | 0 |
| 2026-10-28 | 63K | 195K | 32.2% | 1,200 |
| 2026-10-27 | 70K | 150K | 46.6% | 10 |
| 2026-10-26 | 57K | 152K | 37.5% | 0 |
| 2026-10-23 | 194K | 317K | 61.2% | 150 |
| 2026-10-22 | 220K | 508K | 43.3% | 6,210 |
| 2026-10-21 | 105K | 196K | 53.4% | 0 |
| 2026-10-20 | 118K | 233K | 50.7% | 5,221 |
| 2026-10-19 | 162K | 360K | 45.1% | 0 |
| 2026-10-16 | 153K | 230K | 66.6% | 0 |
| 2026-10-15 | 295K | 419K | 70.3% | 2,793 |
| 2026-10-14 | 102K | 295K | 34.6% | 5,676 |
| 2026-10-13 | 442K | 1.1M | 41.7% | 1,965 |
| 2026-10-12 | 46K | 275K | 16.7% | 0 |
| 2026-10-09 | 122K | 175K | 70.0% | 900 |
| 2026-10-08 | 47K | 140K | 33.6% | 360 |
| 2026-10-07 | 58K | 102K | 56.7% | 0 |
| 2026-10-06 | 78K | 146K | 53.2% | 6,061 |
| 2026-10-05 | 62K | 133K | 46.8% | 0 |
| 2026-10-02 | 75K | 177K | 42.4% | 10 |
| 2026-10-01 | 249K | 456K | 54.6% | 0 |
| 2026-09-30 | 81K | 269K | 30.2% | 2,010 |
| 2026-09-29 | 148K | 267K | 55.2% | 14 |
| 2026-09-28 | 52K | 107K | 48.3% | 154 |
| 2026-09-25 | 180K | 316K | 57.0% | 16,145 |
| 2026-09-24 | 80K | 150K | 53.4% | 0 |
| 2026-09-23 | 229K | 289K | 79.1% | 1,081 |
| 2026-09-22 | 124K | 216K | 57.7% | 3,329 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in CGTX is 13,905 shares, up 10,294 shares over the last settlement date. Over the last 30 readings it ranged from 5 shares (29 June 2026) to 97,893 shares (16 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 13,905 | $0.86 | $12K |
| 2026-10-09 | 3,611 | $0.90 | $3K |
| 2026-10-08 | 3,211 | $0.94 | $3K |
| 2026-10-01 | 3,621 | $0.96 | $3K |
| 2026-09-23 | 3,827 | $0.98 | $4K |
| 2026-09-21 | 2,421 | $1.04 | $3K |
| 2026-09-18 | 16,196 | $1.06 | $17K |
| 2026-09-11 | 406 | $0.98 | $398 |
| 2026-08-28 | 373 | $1.06 | $395 |
| 2026-08-25 | 796 | $0.98 | $780 |
| 2026-08-14 | 27,169 | $1.04 | $28K |
| 2026-08-12 | 2,983 | $1.02 | $3K |
| 2026-08-03 | 8,179 | $0.89 | $7K |
| 2026-07-21 | 6 | $0.95 | $6 |
| 2026-07-17 | 30,888 | $0.94 | $29K |
| 2026-07-16 | 8,479 | $0.95 | $8K |
| 2026-07-08 | 44,955 | $1.08 | $49K |
| 2026-07-02 | 2,174 | $1.13 | $2K |
| 2026-06-29 | 5 | $1.12 | $6 |
| 2026-06-26 | 1,712 | $1.13 | $2K |
| 2026-06-25 | 3,313 | $1.02 | $3K |
| 2026-06-24 | 200 | $1.65 | $330 |
| 2026-06-23 | 422 | $1.68 | $709 |
| 2026-06-18 | 153 | $1.42 | $217 |
| 2026-06-17 | 193 | $1.26 | $243 |
| 2026-06-16 | 97,893 | $1.21 | $118K |
| 2026-06-09 | 939 | $1.21 | $1K |
| 2026-06-05 | 6,258 | $1.36 | $9K |
| 2026-06-03 | 18 | $1.35 | $24 |
| 2026-06-02 | 98 | $1.25 | $123 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CGTX in the last 90 days. The most recent filings are listed below. Latest filing: BIOS Memory SPV I, LP (Director,TenPercentOwner) on 2026-06-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | BIOS Memory SPV I, LP | Director,TenPercentOwner | Grant | 25K | $0.00 | $0 | 81K |
| 2026-06-17 | RICHSTONE ELLEN B | Director | Grant | 25K | $0.00 | $0 | 84K |
| 2026-06-17 | Wallace Peggy | Director | Grant | 25K | $0.00 | $0 | 111K |
| 2026-06-17 | Monia Brett P | Director | Grant | 25K | $0.00 | $0 | 74K |
| 2026-06-17 | Khattar Jack A. | Director | Grant | 25K | $0.00 | $0 | 74K |
| 2026-06-17 | Fletcher Aaron G.L. | Director, 10% owner | Grant | 25K | $0.00 | $0 | 81K |
| 2026-05-01 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 9K | $1.28 | $11K | 619K |
| 2026-04-16 | Doyle John Brendan | Chief Financial Officer | Buy | 10K | $1.13 | $11K | 628K |
| 2026-04-16 | Ricciardi Lisa | CEO & President | Buy | 9K | $1.10 | $10K | 1.7M |
| 2026-04-16 | Caggiano Anthony | Chief Medical Officer | Buy | 10K | $1.11 | $11K | 875K |
| 2026-02-15 | Ricciardi Lisa | CEO & President | Tax withholding | 6K | $1.12 | $7K | 1.7M |
| 2026-02-15 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 2K | $1.12 | $2K | 618K |
| 2026-02-15 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 5K | $1.12 | $5K | 865K |
| 2026-02-04 | Ricciardi Lisa | CEO & President | Tax withholding | 52K | $1.03 | $53K | 1.7M |
| 2026-02-04 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 27K | $1.03 | $28K | 619K |
| 2026-02-04 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 27K | $1.03 | $28K | 870K |
| 2026-02-03 | Ricciardi Lisa | CEO & President | Tax withholding | 26K | $1.12 | $29K | 1.8M |
| 2026-02-03 | Ricciardi Lisa | CEO & President | Grant | 800K | $0.00 | $0 | 1.8M |
| 2026-02-03 | Doyle John Brendan | Chief Financial Officer | Grant | 200K | $0.00 | $0 | 646K |
| 2026-02-03 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 11K | $1.12 | $13K | 897K |
| 2026-02-03 | Caggiano Anthony | Chief Medical Officer | Grant | 400K | $0.00 | $0 | 908K |
| 2025-12-18 | Ricciardi Lisa | CEO & President | Tax withholding | 23K | $1.50 | $35K | 990K |
| 2025-12-18 | Ricciardi Lisa | CEO & President | Grant | 75K | $0.00 | $0 | 1.0M |
| 2025-12-18 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 20K | $1.50 | $30K | 508K |
| 2025-12-18 | Caggiano Anthony | Chief Medical Officer | Grant | 65K | $0.00 | $0 | 528K |
| 2025-12-18 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 9K | $1.50 | $14K | 446K |
| 2025-12-18 | Doyle John Brendan | Chief Financial Officer | Grant | 30K | $0.00 | $0 | 455K |
| 2025-09-19 | Fletcher Aaron G.L. | Director, 10% owner | Exercise or conversion | 8K | $0.84 | $6K | 56K |
| 2025-07-29 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 20K | $0.67 | $14K | 463K |
| 2025-07-29 | Caggiano Anthony | Chief Medical Officer | Grant | 65K | $0.00 | $0 | 484K |
| 2025-07-29 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 9K | $0.67 | $6K | 425K |
| 2025-07-29 | Doyle John Brendan | Chief Financial Officer | Grant | 30K | $0.00 | $0 | 435K |
| 2025-07-29 | Ricciardi Lisa | CEO & President | Tax withholding | 23K | $0.67 | $16K | 939K |
| 2025-07-29 | Ricciardi Lisa | CEO & President | Grant | 75K | $0.00 | $0 | 962K |
| 2025-06-18 | BIOS Advisors GP, LLC | Director,TenPercentOwner | Grant | 34K | $0.00 | $0 | 49K |
| 2025-06-18 | BIOS Fund III, LP | Director,TenPercentOwner | Grant | 34K | $0.00 | $0 | 49K |
| 2025-06-18 | Kreis Leslie W. | Director, 10% owner | Grant | 34K | $0.00 | $0 | 49K |
| 2025-06-18 | Fletcher Aaron G.L. | Director, 10% owner | Grant | 34K | $0.00 | $0 | 49K |
| 2025-06-18 | Khattar Jack A. | Director | Grant | 34K | $0.00 | $0 | 49K |
| 2025-06-18 | Wallace Peggy | Director | Grant | 34K | $0.00 | $0 | 86K |
| 2025-06-18 | RICHSTONE ELLEN B | Director | Grant | 34K | $0.00 | $0 | 59K |
| 2025-06-18 | Monia Brett P | Director | Grant | 34K | $0.00 | $0 | 49K |
| 2025-05-01 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 10K | $0.45 | $4K | 405K |
| 2025-02-15 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 2K | $0.59 | $1K | 414K |
| 2025-02-15 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 5K | $0.59 | $3K | 419K |
| 2025-02-15 | Ricciardi Lisa | CEO & President | Tax withholding | 7K | $0.59 | $4K | 887K |
| 2025-02-04 | Ricciardi Lisa | CEO & President | Grant | 631K | $0.00 | $0 | 894K |
| 2025-02-04 | Doyle John Brendan | Chief Financial Officer | Grant | 295K | $0.00 | $0 | 416K |
| 2025-02-04 | Caggiano Anthony | Chief Medical Officer | Grant | 295K | $0.00 | $0 | 424K |
| 2025-02-03 | Ricciardi Lisa | CEO & President | Tax withholding | 29K | $0.67 | $19K | 262K |
| 2025-02-03 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 13K | $0.67 | $9K | 129K |
| 2025-01-31 | Ricciardi Lisa | CEO & President | Buy | 39K | $0.77 | $30K | 39K |
| 2024-06-07 | Monia Brett P | Director | Grant | 9K | $0.00 | $0 | 15K |
| 2024-06-07 | RICHSTONE ELLEN B | Director | Grant | 9K | $0.00 | $0 | 25K |
| 2024-06-07 | Khattar Jack A. | Director | Grant | 9K | $0.00 | $0 | 15K |
| 2024-06-07 | Wallace Peggy | Director | Grant | 9K | $0.00 | $0 | 52K |
| 2024-06-07 | Bios Equity Partners II, LP | Director,TenPercentOwner | Grant | 9K | $0.00 | $0 | 15K |
| 2024-06-07 | Kreis Leslie W. | Director,TenPercentOwner | Grant | 9K | $0.00 | $0 | 15K |
| 2024-05-01 | Doyle John Brendan | Chief Financial Officer | Tax withholding | 9K | $1.95 | $17K | 121K |
| 2024-03-14 | Ricciardi Lisa | CEO & President | Buy | 6K | $1.75 | $10K | 291K |
| 2024-02-15 | Ricciardi Lisa | CEO & President | Grant | 75K | $0.00 | $0 | 286K |
| 2024-02-15 | Caggiano Anthony | Chief Medical Officer | Grant | 60K | $0.00 | $0 | 142K |
| 2024-02-15 | Doyle John Brendan | Chief Financial Officer | Grant | 20K | $0.00 | $0 | 130K |
| 2024-02-03 | Ricciardi Lisa | CEO & President | Tax withholding | 28K | $2.29 | $64K | 211K |
| 2024-02-03 | Caggiano Anthony | Chief Medical Officer | Tax withholding | 13K | $2.29 | $29K | 82K |
| 2023-11-08 | Fletcher Aaron G.L. | Director,TenPercentOwner | Grant | 500K | $1.05 | $525K | 500K |
| 2023-11-08 | BIOS Fund III, LP | Director,TenPercentOwner | Grant | 500K | $1.05 | $525K | 500K |
| 2023-06-09 | Khattar Jack A. | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-09 | RICHSTONE ELLEN B | Director | Grant | 6K | $0.00 | $0 | 16K |
| 2023-06-09 | Wallace Peggy | Director | Grant | 6K | $0.00 | $0 | 44K |
| 2023-06-09 | Monia Brett P | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-09 | BIOS Fund I, LP | Director,TenPercentOwner | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-09 | BIOS Memory SPV II, LP | Director,TenPercentOwner | Grant | 6K | $0.00 | $0 | 6K |
| 2023-05-01 | Doyle John Brendan | Chief Financial Officer | Grant | 110K | $0.00 | $0 | 110K |
| 2023-02-03 | Ricciardi Lisa | CEO & President | Grant | 214K | $0.00 | $0 | 238K |
| 2023-02-03 | Caggiano Anthony | Chief Medical Officer | Grant | 94K | $0.00 | $0 | 94K |
| 2022-11-29 | RICHSTONE ELLEN B | Director | Buy | 10K | $2.66 | $27K | 10K |
| 2022-11-28 | BIOS Fund III QP, LP | Director,TenPercentOwner | Buy | 2K | $2.65 | $5K | 327K |
| 2022-11-28 | BIOS Fund III QP, LP | Director,TenPercentOwner | Buy | 2K | $2.65 | $5K | 310K |
| 2022-11-28 | BIOS Fund III QP, LP | Director,TenPercentOwner | Buy | 12K | $2.65 | $32K | 2.0M |
| 2022-11-28 | BIOS Fund I QP, LP | Director,TenPercentOwner | Buy | 2K | $2.65 | $5K | 327K |
| 2022-11-28 | BIOS Fund I QP, LP | Director,TenPercentOwner | Buy | 12K | $2.65 | $32K | 2.0M |
| 2022-11-28 | BIOS Fund I QP, LP | Director,TenPercentOwner | Buy | 2K | $2.65 | $5K | 310K |
| 2022-11-16 | BIOS Fund III NT, LP | TenPercentOwner | Buy | 9K | $1.40 | $12K | 325K |
| 2022-11-16 | BIOS Fund III NT, LP | TenPercentOwner | Buy | 54K | $1.40 | $76K | 2.0M |
| 2022-11-16 | BIOS Fund III NT, LP | TenPercentOwner | Buy | 8K | $1.40 | $12K | 308K |
| 2022-11-16 | BIOS Fund I, LP | TenPercentOwner | Buy | 9K | $1.40 | $12K | 325K |
| 2022-11-16 | BIOS Fund I, LP | TenPercentOwner | Buy | 54K | $1.40 | $76K | 2.0M |
| 2022-11-16 | BIOS Fund I, LP | TenPercentOwner | Buy | 8K | $1.40 | $12K | 308K |
| 2022-11-15 | Cavu Management, LP | TenPercentOwner | Buy | 184K | $1.20 | $221K | 316K |
| 2022-11-15 | Cavu Management, LP | TenPercentOwner | Buy | 175K | $1.20 | $210K | 300K |
| 2022-11-15 | Cavu Management, LP | TenPercentOwner | Buy | 1.1M | $1.20 | $1.4M | 2.0M |
| 2022-11-15 | BIOS Fund I QP, LP | TenPercentOwner | Buy | 184K | $1.20 | $221K | 316K |
| 2022-11-15 | BIOS Fund I QP, LP | TenPercentOwner | Buy | 175K | $1.20 | $210K | 300K |
| 2022-11-15 | BIOS Fund I QP, LP | TenPercentOwner | Buy | 1.1M | $1.20 | $1.4M | 2.0M |
| 2022-11-15 | Wallace Peggy | Director | Buy | 13K | $1.20 | $15K | 38K |
| 2022-11-15 | Ricciardi Lisa | CEO & President | Buy | 12K | $1.30 | $16K | 25K |
| 2022-09-27 | Wallace Peggy | Director | Other transaction | 22K | $0.00 | $0 | 25K |
| 2022-09-27 | Golden Seeds Cognition Therapeutics LLC | TenPercentOwner | Other transaction | 2.5M | $0.00 | $0 | 0 |
| 2021-10-13 | Fletcher Aaron G.L. | Director,TenPercentOwner | Conversion | 1.4M | price not stated in the filing | not stated | 1.4M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of CGTX in their latest filing, all on Schedule 13D (active intent). The largest reported stake is AARON G.L. FLETCHER at 6.9% of the class (6,059,555 shares), filed 2025-09-23 for an event on 2025-09-19.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2025-09-23 | 13D/Ano. 4 | AARON G.L. FLETCHERindividual | 6.1M | 6.9% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS ADVISORS GP, LLCpartnership | 6.0M | 6.8% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS CAPITAL MANAGEMENT, LPpartnership | 6.0M | 6.8% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | CAVU MANAGEMENT, LPpartnership | 5.5M | 6.3% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | LESLIE W. KREISindividual | 5.5M | 6.3% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | CAVU ADVISORS, LLCpartnership | 5.5M | 6.3% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS EQUITY PARTNERS III, LPpartnership | 2.7M | 3.0% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND III QP, LPpartnership | 2.0M | 2.3% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS MEMORY SPV I, LPpartnership | 1.4M | 1.6% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS EQUITY PARTNERS, LPpartnership | 1.1M | 1.2% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS CLINICAL OPPORTUNITY FUND, LPpartnership | 500K | 0.6% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS EQUITY COF, LPpartnership | 500K | 0.6% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND I, LPpartnership | 419K | 0.5% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS MEMORY SPV II, LPpartnership | 385K | 0.4% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND III NT, LPpartnership | 327K | 0.4% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS EQUITY PARTNERS II, LPpartnership | 368K | 0.4% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND III, LPpartnership | 310K | 0.4% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND I QP, LPpartnership | 245K | 0.3% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND II QP, LPpartnership | 256K | 0.3% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND II, LPpartnership | 78K | 0.1% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BP DIRECTORS, LPpartnership | 32K | 0.0% | 2025-09-19 |
| 2025-09-23 | 13D/Ano. 4 | BIOS FUND II NT, LPpartnership | 34K | 0.0% | 2025-09-19 |
13F holders
Tracked managers holding CGTX at their latest 13F. JSON1 of the 30 tracked managers held CGTX at their latest 13F, $797K in total at quarter-end prices. Renaissance Technologies is the largest at $797K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 693K | $797K | 0.00% | -424K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Cognition Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cognition Therapeutics (CGTX), SEC CIK 1455365, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2025-09-23.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-07.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1455365Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of CGTX is sold short?
7,037,336 shares were held short at the 2026-10-15 settlement, 9.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CGTX's daily short volume?
On 2026-11-02, 117,866 of the 210,425 CGTX shares reported to FINRA were sold short, 56.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CGTX have fails to deliver?
The SEC's latest file shows 13,905 CGTX shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are CGTX insiders buying or selling?
No open-market insider trades were reported for CGTX in the last 90 days. The most recent filings are listed below. Latest filing: BIOS Memory SPV I, LP (Director,TenPercentOwner) on 2026-06-17.
Who owns 5% or more of CGTX?
6 holders report 5% or more of CGTX in their latest filing, all on Schedule 13D (active intent). The largest reported stake is AARON G.L. FLETCHER at 6.9% of the class (6,059,555 shares), filed 2025-09-23 for an event on 2025-09-19.
Which tracked 13F managers own CGTX?
1 of the 30 tracked 13F managers held CGTX shares at their latest filing, $797K in all. The largest: Renaissance Technologies (693K shares, $797K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.